Slide 1: Atomo Investor Webinar Presentation announcement
ASX Announcement 25 August 2022 For personal use only Atomo Investor Webinar Presentation Friday 26 August 2022 from 12:30pm AEST / 10:30am AWST - Atomo Diagnostics Limited (ASX:AT1) (Atomo) is pleased to announce its participation in the ShareCafe Small Cap "Hidden Gems" Webinar. Chief Financial Of
Slide 2: FY22 Results
Atomo Dia gnos tics Limite d Au t h o ris e d b y J o h n Ke lly, Ma n a g in g Dire c t o r Le ve l 1, 3 -5 Ge o rg e St re e t Le ic h h a rd t NSW 20 4 0 For personal use only Au s t ra lia FY22 RES ULTS 2 5 AUGUST 2 0 2 2 ATOMO DIAGNOS TICS LIMITED | (AS X: AT1) PRIVATE AND CONFIDENTIAL ATOMO DI
Slide 3: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on omissions from, any other written or oral communications transmitted or otherwise made information available as at the date of this presentation. The information in this available to
Slide 4: Key Value Drivers
KEY VALUE DRIVERS For personal use only 1 A visionary diagnostics company reimaging consumer focused testing and delivering best in class usability in the growing point of care and decentralised test market Strong financial position, committed investors, an experienced board & 2 management team and
Slide 5: Company Summary
CO MPANY SUMMARY For personal use only Atomo Diagnostics Limited (ASX: AT1) is an innovative medical device diagnostics company supplying unique, integrated user friendly rapid diagnostic test (RDT) devices and finished point-of-care rapid tests to global partners Headquartered in Australia and list
Slide 6: FY22 Key Achievements and Challenges
F Y2 2 KEY ACHIEVEMENTS AND CHALLENGES For personal use only Completion of industralisation of operations to support volume production of 1 Atomo products, including blister manufacturing – up to 18 million per annum of installed cassette capacity now available Successful participation in the local
Slide 7: FY22 Financial Results
For personal use only FY22 FINANCIAL RESULTS ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) PRIVATE AND CONFIDENTIAL 6
Slide 8: FY22 Profit & Loss
F Y2 2 - P RO F IT & LO SS For personal use only AUD FY22($m) FY21($m) (%) Annual Sales Revenue ($m) Revenue 12.34 6.72 84% Cost of sales (8.09) (3.30) (145%) Gross Profit 4.25 3.42 24% 14.0 Gross Margin 34% 51% 12.0 10.0 Licence and settlement fee income 1.65 - 100% 8.0 Total revenue 13.99 6.72 108
Slide 9: FY22 Balance Sheet
F Y2 2 - BALANCE SHEET For personal use only FY22 FY21 • Cash balance of $12.97m at 30 June 22 and debt free AUD ($m) ($m) • COVID-19 stock on hand at year end continuing to be sold Cash and cash equivalents 12.97 17.95 over FY23 Trade and other receivables 2.68 4.49 • Continued investment in manufa
Slide 10: FY22 Cash Flow
F Y2 2 - CASH F LOW For personal use only • Cash receipts of $16.39m from customers as strong COVID sales, together with growing HIV business and the settlement and licence fees from Access Bio, drove cash inflows • Cash payments for stock of $8.83m related primarily to purchase of COVID-19 rapid te
Slide 11: Business Summary
For personal use only BUSINESS SUMMARY ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) PRIVATE AND CONFIDENTIAL 10
Slide 12: Atomo's Strategic Focus
ATO MO ’S STRATEGIC FO CUS For personal use only CO RE CAP ABILITIES Innovation, Co-development & Commercialisation (Device Design, Usability, Manufacturability, IP, Regulatory, Co-commercialisation) MARKETS Consumer Health Infectious Diseases Testing OEM Devices (HIV, COVID, HCV and Others) & Welln
Slide 13: Product Channels
P RO DUCT CHANNELS For personal use only CHANNELS* Consumer Health Infectious Diseases Testing OEM Devices (HIV, COVID, HCV and Others) & Wellness (Blisters, Devices, Components, Licenses) (Retail and Emerging Telehealth) Healthcare Distributors Diagnostics companies suppling finished rapid tests Di
Slide 14: Unique Technology & Know How
For personal use only UNIQ UE TECHNO LO GY & KNOW HOW ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) PRIVATE AND CONFIDENTIAL 13
Slide 15: Atomo's Blood Testing Solutions
ATO MO ’S BLO O D TESTING SO LUTIO NS For personal use only * ** IN MARKET Galileo: supports professional & self- test applications. WHO Prequalified. Pascal: with integrated buffer, supports professional & self-test applications: Pregnancy test, NG – CE Mark FebriDx, Lumos – CE Mark and TGA Elion:
Slide 16: Atomo Swab Platform
ATO MO SWAB P LATFO RM For personal use only The Atomo Swab Platform is a unique (patent pending*) device developed using Atomo’s existing core IP and knowhow. Developed to improve usability and performance of swab-based rapid tests, this product expands Atomo’s product range beyond blood-based test
Slide 17: Operational Capability & Expertise
O P ERATIO NAL CAPABILITY & EXP ERTISE For personal use only Atomo’s Gen II Blister machine currently being qualified in Sydney Atomo has used proceeds from the IPO to expand its manufacturing capabilities to enable the company to commercialise a larger range of finished home tests, and to deliver i
Slide 18: Regulatory Approvals
REGULATO RY AP P ROVALS For personal use only CE MARK ( Notified Body BSI ) : PASCAL and GALILEO – both approved for Professional Use and Self Test SymplitudebyMe HIV Self Test (Atomo), AtomoRapid HIV Prof. Use (Atomo), Pregnancy hCG Prof use (NG Bio), Pregnancy hCG Self-Test (NG Bio), FebriDx AMR s
Slide 19: A Leading HIV Rapid Test
A LEADING HIV RAP ID TEST For personal use only Atomo has developed and successfully launched the world’s first integrated, blood-based RDT solutions for professional use and self-test HIV screening: • With regulatory approvals including CE Mark for Europe, Australian TGA, and prequalification by th
Slide 20: Other Finished Tests
OTHER F INISHED TESTS For personal use only Atomo has partnered with NG Biotech and Lumos Diagnostics to provide the cassettes used to produce the Blood Precision hCG Pregnancy Test and FebriDx Antimicrobial Resistance (AMR) screening tests • The Blood Precision hCG pregnancy test offers results in
Slide 21: Growth Strategy
For personal use only GROW TH STRATEGY ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) PRIVATE AND CONFIDENTIAL 20
Slide 22: Diagnostic Landscape and Trends
DIAGNO STIC LANDSCAP E AND TRENDS HIV P O INT O F CARE P RO LIF ERATIO N For personal use only COVID 19 has transformed the diagnostic Growth in rapid testing testing landscape • Growing demand for reliable, rapid and decentralised diagnostic testing for patients at POC and in their homes * • While
Slide 23: Expanding Demand for OEM Supply
Marke EXPANDING DEMAND FO R O EM SUP P LY HIV t P o st COVID, At o m o is a c t ive ly e n g a g in g w it h a re c e p t ive d ia g n o st ic m a rke t For personal use only Resurgent Interest in New Products and Home Testing • Atomo has seen an increase in enquiries and interest in new test develo
Slide 24: Finished Product Strategy
F INISHED P RO DUCT STRATEGY For personal use only Over the last 6 months, Atomo has been focusing on development of P RO DUCT REQ UIREMENTS a go-to-market and product partnership strategy involving a number of key elements shown REGULATORY PATH • Channel partner feedback on prioritisation of custom
Slide 25: Commercialisation Product Roadmap
CO MMERCIALISATIO N P RO DUCT ROADMAP For personal use only Atomo has reviewed the changing point of care test landscape post pandemic, including engagement with emerging eHealth companies now opening up home based healthcare. This assessment of emerging product demand, technical feasibility, regula
Slide 26: Strategy for FY23 and Beyond
STRATEGY FO R F Y2 3 AND BEYO ND For personal use only Switching focus and investment from expansion of installed manufacturing capacity (now complete) to commercial scale up and business development, including focusing on: • Expansion of senior commercial resourcing and associated engagement with m
Slide 27: Appendix
Atomo Dia gnos tics Limite d Le ve l 1, 3 -5 Ge o rg e St re e t Le ic h h a rd t NSW 20 4 0 For personal use only Au s t ra lia AP P ENDIX 2 3 AUGUST 2 0 2 2 ATOMO DIAGNOS TICS LIMITED | (AS X: AT1) PRIVATE AND CONFIDENTIAL ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) PRIVATE AND CONFIDENTIAL
Slide 28: Our Team: Board
O UR TEAM Bo a rd For personal use only J o h n Ke it h Dr. Cu rt La Be lle De b o ra h J . Ne ff Dr. P a u l Ka s ia n Non -Executive Chair Non -Executive Director Non -Executive Director Non -Executive Director Mr. Keith is one of the Managing Dr. LaBelle has been actively A veteran of the life sc
Slide 29: Our Team: Executive Team
O UR TEAM Exe c u t ive Te a m For personal use only J o h n Ke lly W ill So u t e r Ch a n d ra Su ku m a r Dr. Ma rilyn Cla rke Founder, Managing Director Chief Financial Officer Chief Operating Officer Director, Quality Assurance and CEO & Regulatory Affairs Before founding Atomo Diagnostics Expe
Slide 30: Our Team: Commercial Team
O UR TEAM Co m m e rc ia l Te a m For personal use only J im Mc Me n a m y An n a Tu c ke r J a s o n Ka va n a g h Head of Business Development Vice President of Business Business Development and Partnerships – U.S.A Development - Europe Manager - APAC Mr. McMenamy has over 30 years of Ms. Tucker b
Slide 31: Company History
CO MPANY HISTO RY Recent Milestones For personal use only • 2010: Atomo formed to address Australian TGA Atomo Deal with Galileo secures Atomo A$16m in HIV Self Test unmet user needs and reliability approves Atomo successfully Accessbio for FDA EUA with incorporates customer secures WHO issues in po
Slide 32: Patented Portfolio
PATENTED P O RTFO LIO * For personal use only • Family 1: Diagnostic System PCT/AU2011/000315 Relates to an integrated test system incorporating lancet, test, and internal buffer reservoir. The system is such that buffer is brought into contact with the test component only after the sample has been